Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for chronic coughers: experimental drug enters final testing phase

NCT ID NCT07650084

Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called BLU-5937 in adults who have had a stubborn cough for at least a year that hasn't improved with other treatments. About 75 people in China will receive either the drug or a placebo for 24 weeks to see if it reduces coughing and is safe. The goal is to find a new option for people whose chronic cough severely affects their daily life.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 75 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Capable of giving signed informed consent * Refractory chronic cough (including unexplained chronic cough) for at least one year * Women of child-bearing potential must use a highly effective contraception method during the study and for at least 14 days after the last dose Exclusion Criteria: * Current smoker/vaper (all forms of smoking and inhaled substances, including, cannabis/tobacco smoke and nicotine vapors) or individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history * Diagnosis of chronic obstructive pulmonary disease, bronchiectasis, chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, uncontrolled asthma, or other significant or progressive airway/respiratory disorder that might affect cough based on clinician assessment * Respiratory tract infection within 4 weeks before screening * Laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection at screening * History of malignancy in the last 5 years * History of alcohol or drug abuse within the last 3 years * Has a positive serologic test for human immunodeficiency virus (HIV), hepatitis B virus surface antigen, or hepatitis C virus. * Previous participation in a BLU-5937 trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Refractory chronic cough are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Chronic Cough Cough

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Refractory chronic cough

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    38 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • GSK Investigational Site

    RECRUITING

    Leshan, Sichuan, 614003, China

  • GSK Investigational Site

    RECRUITING

    Beijing, 100730, China

  • GSK Investigational Site

    RECRUITING

    Changsha, 410008, China

  • GSK Investigational Site

    RECRUITING

    Chengdu, 610021, China

  • GSK Investigational Site

    RECRUITING

    Chengdu, 610041, China

  • GSK Investigational Site

    RECRUITING

    Chongqing, 408099, China

  • GSK Investigational Site

    RECRUITING

    Dongguan, 523326, China

  • GSK Investigational Site

    RECRUITING

    Ganzhou, 341000, China

  • GSK Investigational Site

    RECRUITING

    Guangzhou, 510000, China

  • GSK Investigational Site

    RECRUITING

    Guangzhou, 510260, China

  • GSK Investigational Site

    RECRUITING

    Guilin, 541002, China

  • GSK Investigational Site

    RECRUITING

    Hangzhou, 310003, China

  • GSK Investigational Site

    RECRUITING

    Hefei, 230001, China

  • GSK Investigational Site

    RECRUITING

    Hefei, 230022, China

  • GSK Investigational Site

    RECRUITING

    Hohhot, 010017, China

  • GSK Investigational Site

    RECRUITING

    Huizhou, 516000, China

  • GSK Investigational Site

    RECRUITING

    Huizhou, 516001, China

  • GSK Investigational Site

    RECRUITING

    Jiangsu, 221004, China

  • GSK Investigational Site

    RECRUITING

    Jinan, 250021, China

  • GSK Investigational Site

    RECRUITING

    Kunming, 650032, China

  • GSK Investigational Site

    RECRUITING

    Liuzhou, China

  • GSK Investigational Site

    RECRUITING

    Meizhou, 514700, China

  • GSK Investigational Site

    RECRUITING

    Nanchang, 330038, China

  • GSK Investigational Site

    RECRUITING

    Pingxiang, 337055, China

  • GSK Investigational Site

    RECRUITING

    Shanghai, 200032, China

  • GSK Investigational Site

    RECRUITING

    Shanghai, 200065, China

  • GSK Investigational Site

    RECRUITING

    Shanghai, 200080, China

  • GSK Investigational Site

    RECRUITING

    Shenyang, 110004, China

  • GSK Investigational Site

    RECRUITING

    Shenzhen, 518053, China

  • GSK Investigational Site

    RECRUITING

    Taizhou, 317000, China

  • GSK Investigational Site

    RECRUITING

    Ürümqi, 830001, China

  • GSK Investigational Site

    RECRUITING

    Weifang, China

  • GSK Investigational Site

    RECRUITING

    Wuxi, 214023, China

  • GSK Investigational Site

    RECRUITING

    Xiamen, 361004, China

  • GSK Investigational Site

    RECRUITING

    Yangzhou, 225001, China

  • GSK Investigational Site

    RECRUITING

    Yinchuan, China

  • GSK Investigational Site

    RECRUITING

    Zhanjiang, 524045, China

  • GSK Investigational Site

    RECRUITING

    Zhengzhou, 450052, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.